Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ANGLE plc ( (GB:AGL) ) has issued an announcement.
ANGLE plc announced successful results from its dual analysis workflow for circulating tumour DNA (ctDNA) and CTC-DNA using Illumina’s platform. This breakthrough allows for the detection of a wider range of cancer mutations from a single blood sample, providing important biomarkers that can guide treatment. The findings underscore the importance of utilizing both CTC and ctDNA analyses, as they identified twice as many mutations when combined compared to using ctDNA alone. This advancement positions ANGLE strongly within the liquid biopsy market, enhancing its collaboration with Illumina, and offering significant potential for more comprehensive cancer profiling and personalized treatment plans.
More about ANGLE plc
ANGLE plc is a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology. The company is recognized for its Parsortix system, which facilitates the collection and analysis of CTCs, enabling comprehensive genomic and proteomic profiling from simple blood samples. ANGLE focuses on clinical services and diagnostic products, operating through GCLP-compliant laboratories and offering custom assay development and clinical trial testing.
YTD Price Performance: 34.15%
Average Trading Volume: 1,226,957
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £41.93M
See more insights into AGL stock on TipRanks’ Stock Analysis page.
